High-Risk Cancer

24 registered clinical trials studyying High-Risk Cancer — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer NCT06908031	Sixth Affiliated Hospital, Sun Yat-sen University	Phase 2
Recruiting	Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Ca NCT06277050	Jiangxi Provincial Cancer Hospital	Phase 3
Active Not Recruiting	Adherence to Lung Cancer Screening by Low-dose Thoracic CT in Haut-Rhin Department, France. NCT06020443	Groupe Hospitalier de la Region de Mulhouse et Sud Alsace	N/A
Not Yet Recruiting	Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation NCT06041490	Peking Union Medical College Hospital	Phase 2
Recruiting	Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermedia NCT05498272	Rana McKay, MD	Phase 2
Recruiting	Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotio NCT05557487	Gee-Chen Chang	—
Completed	Standalone Observational Study Assessing the Performance of an AI/ML Tech-based SaMD on Chest LDCT Images (REA NCT06576232	Median Technologies	—
Completed	Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population Wi NCT06751576	Median Technologies	—
Recruiting	Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens NCT06327568	European Institute of Oncology	—
Recruiting	Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer NCT05013216	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 1
Completed	Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region NCT05482880	Maastricht University Medical Center	—
Active Not Recruiting	Needs and Preferences of Patients With Head-neck Cutaneous SCC NCT06046625	Maastricht University Medical Center	—
Unknown	Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL NCT05254899	Chinese Academy of Medical Sciences	Phase 2
Withdrawn	Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasiv NCT05120622	University of British Columbia	Phase 1 / Phase 2
Unknown	Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study NCT04334993	Israeli Medical Association	Phase 2
Active Not Recruiting	Three Fraction Radiation to Induce Immuno-Oncologic Response NCT03978663	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	N/A
Active Not Recruiting	Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis NCT04217356	University Health Network, Toronto	—
Unknown	A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Specia NCT04905329	Moscow Clinical Scientific Center	—
Recruiting	Prevent Cancer- Greenville NCT04947098	Prisma Health-Upstate	—
Unknown	Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer NCT04740866	Cairo University	N/A
Completed	Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients NCT02308280	Maisonneuve-Rosemont Hospital	Phase 2
Completed	Adjunctive Smart Phone Based Smoking Cessation Treatment NCT03343249	University of Texas Southwestern Medical Center	N/A
Terminated	Neoadjuvant Chemotherapy With Cabazitaxel NCT01941550	RWTH Aachen University	Phase 2
Terminated	Fenretinide in Healthy Young Women at Genetic and Familial Risk NCT01479192	European Institute of Oncology	Phase 3